Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 53

Sort by

Sort Order Select

Journal Articles

Co-Targeting of CD38 and CD47 in T Cell Acute Lymphoblastic Leukemia

Fotini Vogiatzi, PhD, Kristina Müller, Dorothee Winterberg, Thies Rösner, PhD, Lennart Lenk, PhD, Gunnar Cario, MD PhD, Martin Schrappe, MDPhD, Andreas E. Kulozik, MD PhD, Beat Bornhauser, Jean-Pierre Bourquin, MD PhD, Thomas Valerius, MD, Matthias Peipp, PhD, Christian Kellner, PhD, Denis Martin Schewe, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-140270

Published: 2020

Journal Articles

Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia Harboring Heterogeneous Genomic Profiles Respond to Venetoclax in Combination with Chemotherapy

Andrew E. Place, MDPhD, Seth E. Karol, MD, Christopher J. Forlenza, MD, Marion Gambart, MD, Todd M. Cooper, DO, Christopher Fraser, MBBS, Gunnar Cario, MD PhD, Maureen M O'Brien, MD, Nicolas U. Gerber, MD, Phillip Barnette, MD, Dirk Reinhardt, MDPhD, Giridharan Ramsingh, MD, Bo Tong, PhD, Kristina Unnebrink, PhD, Deeksha Vishwamitra, PhD, Fengjiao Dunbar, PhD, Betty A. Prine, BS, Tammy L. Palenski, PhD, Mignon L. Loh, MD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-137376

Published: 2020

Journal Articles

In Vitro Drug Response Profiling in BCP- and T-ALL Primary Samples Adds a Robust Functional Layer Enabling Optimized Guidance of Individualized Therapy in Relapsed and Refractory Pediatric Acute Leukemia Patients

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-142314

Published: 2020

Journal Articles

Poor Prognosis in Children with ABL -Class Fusion Positive B-Cell Acute Lymphoblastic Leukemia Treated According to AIEOP-BFM Protocols

Blood (2019) 134 (Supplement_1): 1351.

https://doi.org/10.1182/blood-2019-126523

Published: 2019

Journal Articles

Incidence of Hypersensitivity Reactions (HSR) Reactions (HSR) to Peg-Asparaginase (PEG-ASP) in 6136 Patients Treated in the AIEOP-BFM ALL 2009 Study Protocol

Carmelo Rizzari, Anja Moericke, MD, Valentino Conter, MD, Maria Grazia Valsecchi, PhD, Martin Zimmermann, PhD, Daniela Silvestri, Georg Mann, MD, Felix Niggli, MD, Luciano Dalla-Pozza, MBBS FRACP, Jan Stary, Prof., MD PhD, Sarah Elitzur, MD, Gunnar Cario, MD, Franco Locatelli, MD, Joachim Boos, MD, Massimo Zucchetti, PharmD, Andrea Biondi, MD, Martin Schrappe, MD PhD

Blood (2019) 134 (Supplement_1): 2589.

https://doi.org/10.1182/blood-2019-123448

Published: 2019

Journal Articles

Urine Proteomic Analysis Reveals Disease-Specific Patterns in Pediatric Patients with Classical Hodgkin's Disease(HD). an Addon Study to the Euronet-PHL-C2 Trial

Blood (2019) 134 (Supplement_1): 2804.

https://doi.org/10.1182/blood-2019-125611

Published: 2019

Journal Articles

Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Phase 1 Study

Seth E Karol, MD, Todd M Cooper, DO, Henrique Bittencourt, Lia Gore, MD, Maureen M O'Brien, MD, Christopher Fraser, MD, Marion Gambart, MD, Gunnar Cario, MD PhD, Christian Michel Zwaan, MD PhD, Jean-Pierre Bourquin, MD PhD, Mignon L. Loh, MD, Hubert Caron, MD PhD, Betty Prine, Ahmed Hamed Salem, PhD FCP, Kristina Unnebrink, Bo Tong, PhD, Tammy Palenski, PhD, Andrew E. Place, MD PhD

Blood (2019) 134 (Supplement_1): 2649.

https://doi.org/10.1182/blood-2019-129805

Published: 2019

Journal Articles

CD79a Is Associated with Central Nervous System Infiltration of Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia

Lennart Lenk, PhD MSc, Fotini Vogiatzi, PhD, Michela Carlet, PhD, Christian Vokuhl, MD, Gunnar Cario, MD, Martin Schrappe, MD PhD, Irmela Jeremias, MD PhD, Stephan Fuhrmann, MD, Elias Hobeika, PhD, Hassan Jumaa, Prof. Dr., Ameera Alsadeq, PhD, Denis Martin Schewe, MD

Blood (2018) 132 (Supplement 1): 386.

https://doi.org/10.1182/blood-2018-99-114595

Published: 2018

Journal Articles

Venetoclax Enhances the Efficacy of Therapeutic Antibodies in B-Cell Malignancies

Fotini Vogiatzi, PhD, Julia Heymann, Thies Rösner, PhD, Lennart Lenk, PhD MSc, Gunnar Cario, MD, Martin Schrappe, MD PhD, Beat Bornhauser, PhD, Jean-Pierre Bourquin, MD PhD, Simon Bomken, MD, Thomas Valerius, MD, Matthias Peipp, PhD, Christian Kellner, PhD, Denis Martin Schewe, MD

Blood (2018) 132 (Supplement 1): 4177.

https://doi.org/10.1182/blood-2018-99-114677

Published: 2018

Journal Articles

Methotrexate-Associated Toxicity in Children with Down Syndrome and Acute Lymphoblastic Leukemia during Consolidation Therapy with High Dose Methotrexate According to ALL-BFM Treatment Regimen

Mirko Kroll, Kirsten Bleckmann, MD, Anja Möricke, MD, Denis Martin Schewe, MD, Martin Stanulla, MD PhD, Martin Zimmermann, PhD, Martin Schrappe, MD PhD, Gunnar Cario, MD

Blood (2018) 132 (Supplement 1): 1378.

https://doi.org/10.1182/blood-2018-99-112114

Published: 2018

Journal Articles

Pediatric T-ALLs Developing into a Type 2 Relapse Originate from Cells That Carry the Potential of Variable Maturation into Subclones with Distinct Chromatin Landscapes

Blood (2018) 132 (Supplement 1): 1545.

https://doi.org/10.1182/blood-2018-99-118255

Published: 2018

Journal Articles

Longitudinal Multilevel Omic Analysis of Pediatric T-ALL Reveals Distinct Mechanisms for Disease Progression in Type 1 and in Type 2 Relapses

Blood (2018) 132 (Supplement 1): 2826.

https://doi.org/10.1182/blood-2018-99-117978

Published: 2018

Journal Articles

PDX Models Recapitulate Genetics and Epigenetics of Pediatric T-Cell Leukemia

Blood (2017) 130 (Supplement 1): 2723.

https://doi.org/10.1182/blood.V130.Suppl_1.2723.2723

Published: 2017

Journal Articles

Relapsing Pediatric T-Cell Acute Lymphoblastic Leukemia Downregulates T-Cell Properties and Upregulates Cell Adhesion

Blood (2017) 130 (Supplement 1): 2726.

https://doi.org/10.1182/blood.V130.Suppl_1.2726.2726

Published: 2017

Journal Articles

Genome-Wide Association Study (GWAS) of High-Risk Minimal Residual Disease and Relapse in B-Cell Acute Lymphoblastic Leukemia on Trial AIEOP-BFM ALL 2000

Laura Hinze, Stefanie V. Junk, PhD, Norman Klein, Anja Moricke, MD, Gunnar Cario, MD, Christian P. Kratz, MD, Richard S Houlston, MD PhD, Claus R Bartam, MD, Rolf Koehler, PhD, Martin Zimmermann, PhD, Martin Schrappe, MD PhD, Martin Stanulla, MD PhD

Blood (2017) 130 (Supplement 1): 3981.

https://doi.org/10.1182/blood.V130.Suppl_1.3981.3981

Published: 2017

Journal Articles

Targeting of the Interleukin-7 Receptor Alpha-Chain (IL-7Rα) Blocks B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Development and Reduces Leukemic Infiltration to the Central Nervous System (CNS)

Ameera Alsadeq, PhD, Anila George Vadakumchery, Ali Almasri, Hend Abdelrasoul, Markus Werner, PhD, Lennart Lenk, Felix Seyfried, Klaus-Michael Debatin, MD, Lueder-Hinrich Myer, MD, Gunnar Cario, MD, Martin Schrappe, MD PhD, Denis Martin Schewe, MD, Hassan Jumaa, PhD

Blood (2017) 130 (Supplement 1): 479.

https://doi.org/10.1182/blood.V130.Suppl_1.479.479

Published: 2017

Journal Articles

TP53 , ETV6 and RUNX1 Germline Variants in Patients Developing Secondary Neoplasms after Treatment for Childhood Acute Lymphoblastic Leukemia

Stefanie V. Junk, PhD, Norman Klein, Sabine Schreek, Martin Zimmermann, PhD, Anja Möricke, MD, Kirsten Bleckmann, Gunnar Cario, MD, Martin Schrappe, MD PhD, Christian P. Kratz, MD, Martin Stanulla, MD PhD

Blood (2017) 130 (Supplement 1): 884.

https://doi.org/10.1182/blood.V130.Suppl_1.884.884

Published: 2017

Journal Articles

An Fc-Engineered CD19 Antibody Engages Macrophages and Is Effective in Xenograft Models of Pediatric Acute Lymphoblastic Leukemia

Denis M Schewe, MD, Ameera Alsadeq, PhD, Gunnar Cario, MD, Simon Vieth, MD, Thomas Valerius, MD, Martin Schrappe, MD PhD, Martin Gramatzki, MD, Matthias Peipp, PhD, Christian Kellner, PhD

Blood (2016) 128 (22): 277.

https://doi.org/10.1182/blood.V128.22.277.277

Published: 2016

Journal Articles

Zeta-Chain-Associated Protein Kinase-70 (Zap-70) Promotes Acute Lymphoblastic Leukemia (ALL) Infiltration into the Central Nervous System By Enhancing Chemokine Receptor 7 (CCR7) Expression

Ameera Alsadeq, PhD, Henning Fedders, PhD, Steffi Spielberg, Christian Vokuhl, MD, Gunnar Cario, MD, Martin Schrappe, MD PhD, Denis Martin Schewe, MD

Blood (2015) 126 (23): 901.

https://doi.org/10.1182/blood.V126.23.901.901

Published: 2015

Journal Articles

Constitutive Activation of FLT3 Is a Positive Prognostic Factor in Infants with MLL-Rearranged Acute Lymphoblastic Leukemia

Henning Fedders, PhD, Denis Martin Schewe, MD, Martin Zimmermann, PhD, Ameera Alsadeq, PhD, Anja Moericke, MD, Udo zur Stadt, PhD, Martin A. Horstmann, MD, Rob Pieters, MD PhD, Martin Schrappe, MD PhD, Gunnar Cario, MD, Martin Stanulla, MD

Blood (2015) 126 (23): 1417.

https://doi.org/10.1182/blood.V126.23.1417.1417

Published: 2015

NARROW

Co-Targeting of CD38 and CD47 in T Cell Acute Lymphoblastic Leukemia

Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia Harboring Heterogeneous Genomic Profiles Respond to Venetoclax in Combination with Chemotherapy

In Vitro Drug Response Profiling in BCP- and T-ALL Primary Samples Adds a Robust Functional Layer Enabling Optimized Guidance of Individualized Therapy in Relapsed and Refractory Pediatric Acute Leukemia Patients

Poor Prognosis in Children with ABL -Class Fusion Positive B-Cell Acute Lymphoblastic Leukemia Treated According to AIEOP-BFM Protocols

Incidence of Hypersensitivity Reactions (HSR) Reactions (HSR) to Peg-Asparaginase (PEG-ASP) in 6136 Patients Treated in the AIEOP-BFM ALL 2009 Study Protocol

Urine Proteomic Analysis Reveals Disease-Specific Patterns in Pediatric Patients with Classical Hodgkin's Disease(HD). an Addon Study to the Euronet-PHL-C2 Trial

Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Phase 1 Study

CD79a Is Associated with Central Nervous System Infiltration of Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia

Venetoclax Enhances the Efficacy of Therapeutic Antibodies in B-Cell Malignancies

Methotrexate-Associated Toxicity in Children with Down Syndrome and Acute Lymphoblastic Leukemia during Consolidation Therapy with High Dose Methotrexate According to ALL-BFM Treatment Regimen

Pediatric T-ALLs Developing into a Type 2 Relapse Originate from Cells That Carry the Potential of Variable Maturation into Subclones with Distinct Chromatin Landscapes

Longitudinal Multilevel Omic Analysis of Pediatric T-ALL Reveals Distinct Mechanisms for Disease Progression in Type 1 and in Type 2 Relapses

PDX Models Recapitulate Genetics and Epigenetics of Pediatric T-Cell Leukemia

Relapsing Pediatric T-Cell Acute Lymphoblastic Leukemia Downregulates T-Cell Properties and Upregulates Cell Adhesion

Genome-Wide Association Study (GWAS) of High-Risk Minimal Residual Disease and Relapse in B-Cell Acute Lymphoblastic Leukemia on Trial AIEOP-BFM ALL 2000

Targeting of the Interleukin-7 Receptor Alpha-Chain (IL-7Rα) Blocks B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Development and Reduces Leukemic Infiltration to the Central Nervous System (CNS)

TP53 , ETV6 and RUNX1 Germline Variants in Patients Developing Secondary Neoplasms after Treatment for Childhood Acute Lymphoblastic Leukemia

An Fc-Engineered CD19 Antibody Engages Macrophages and Is Effective in Xenograft Models of Pediatric Acute Lymphoblastic Leukemia

Zeta-Chain-Associated Protein Kinase-70 (Zap-70) Promotes Acute Lymphoblastic Leukemia (ALL) Infiltration into the Central Nervous System By Enhancing Chemokine Receptor 7 (CCR7) Expression

Constitutive Activation of FLT3 Is a Positive Prognostic Factor in Infants with MLL-Rearranged Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only